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Abstract  Liver  perfusion  imaging  is  a  quantitative  functional  investigation.  Liver  perfusion
imaging is  complicated  because  of  the  liver’s  dual  vascular  supply,  artefacts  due  to  respiratory
movements  and  the  fenestrated  sinusoidal  capillaries  which  allow  the  contrast  medium  to  dif-
fuse out.  Liver  perfusion  can  be  examined  by  ultrasound,  CT  or  MRI:  each  technique  has  its
limitations  and  speciﬁc  features.  The  major  indications  in  hepatology  are  oncology  (detection,
characterization  and  tumor  response)  and  non-invasive  investigation  of  patients  with  chronic
liver disease.  Work  is  needed  to  standardize  acquisition  and  modeling  methods  to  allow  wider
use of  results  and  more  widespread  use  of  the  technique.
© 2013  Éditions  françaises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
The  liver  is  a  large,  richly  vascularized,  subcutaneous  solid  organ.  It  is  therefore  eas-
ily  accessible  for  various  imaging  modalities  (ultrasound,  computed  tomography  [CT]  and
magnetic  resonance  imaging  [MRI]),  despite  the  fact  that  it  moves  with  the  diaphragm  and
can  deform.  Various  contrast  media,  each  of  which  is  speciﬁc  to  these  individual  methods,
are  also  extremely  useful  and  explain  the  key  role  of  imaging  in  diagnostic  and  therapeutic
hepatology.Perfusion  imaging  provides  information  about  the  tissue  microcirculation,  in  other  words
the  movement  of  water  and  solutes  at  levels  far  below  the  spatial  resolution  of  the  instru-
ment.  It  is  not,  therefore,  a  dynamic  qualitative  analysis  of  what  is  typically  described
as  tissue  enhancement,  but  a  quantitative  extraction  of  descriptive  parameters  of  the
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portal  perfusion  in  order  to  assess  focal  or  diffuse  abnor-324  
iver’s  perfusion  physiology  (Table  1).  It  is  based  on  the  prin-
iple  of  injecting  an  iodinated  contrast  medium  (called  a
racer)  and  recording  curves  showing  the  change  in  its  tis-
ue  concentration  over  time  by  rapid  temporal  samplings.
hese  curves  provide  information  on  the  concentration  of
he  tracer  at  each  point  in  time  and  for  each  image  voxel.
he  parameters  required  are  extracted  from  these  curves
y  adjusting  them  to  mathematical  perfusion  models.  The
ifﬁculty  in  the  case  of  the  liver  is  the  fact  that  it  has  a  dual
ascular  supply,  that  the  acquisition  is  hindered  by  respira-
ory  movements  and  that  the  organ  deforms.  In  addition,  the
inusoidal  capillaries  are  fenestrated  and  the  tracer  there-
ore  readily  diffuses  out  of  them.
The  basic  hypothesis  on  which  liver  perfusion  imaging  is
ased  is  that  local  or  diffuse  pathological  processes  lead  to
easurable  changes  in  these  perfusion  parameters.  Quan-
ifying  these  changes  therefore  provides  information  about
he  presence  or  progression  of  disease  processes.  There  are
wo  indications  for  studying  perfusion  in  hepatology:  oncol-
gy  and  investigation  of  chronic  liver  diseases.  We  shall  start
rom  a  simple  paradigm  based  on  the  relationship  between
he  radiologist  and  clinician  being  organized  around  four
ajor  questions:
is  a  lesion  present,  and  if  so  is  it  an  abnormality,  a  variant
or  a  pathological  process?
if  the  imaging  is  performed  for  detection  purposes,  what
is  the  type  of  process  or  pathology  in  question  and  is  it
related  to  the  underlying  disease?
what  treatment  can  be  considered  depending  on  the  imag-
ing  results?
and  what  is  the  response  to  treatment  and  can
complications  be  diagnosed?
Table  1  The  main  perfusion  parameters  and  their  signiﬁcance
Parameter  Deﬁnition  
Time  to  peak  Time  between  arrival  of  
in  the  large  afferent  vess
maximum  enhancement
Blood  ﬂow  or  perfusion  Volume  of  blood  passing  
region  studied  per  unit  o
Blood  volume  Volume  of  blood  in  a  regi
(vascular,  extravascular)
Mean  transit  time  Mean  time  the  tracer  tak
the  region  studied
Permeability Plasma  ﬂow  leaking  from
vascular  compartment  in
interstitium
Arterial/venous  perfusion  index  Amount  of  blood  entering
region  studied  through  th
arterial/venous  network
K  trans  Transfer  constant  betwee
vascular  compartment  an
extracellular  space
•M.  Ronot  et  al.
After  examining  the  relevant  theoretical  and  method-
logical  questions,  we  will  examine  the  use  of  perfusion
maging  in  detecting  focal  hepatic  lesions,  characterizing
he  lesion  and  studying  tumor  response.
eneral principles
hysiology of the liver
he  liver  has  a dual  blood  supply,  approximately  25%  of
hich  comes  from  the  hepatic  artery  and  the  remaining  75%
rom  the  portal  vein.  There  is  no  hepatic  capillary  network
s  such  and  this  is  replaced  by  fenestrated  sinusoids.  Both
fferent  vascular  systems  communicate  with  each  other
hrough  trans-sinusoidal  and  transvasal  communications  and
hrough  the  peribiliary  plexuses.  A  fundamental  concept
hat  allows  us  to  fully  understand  the  adaptatory  mecha-
isms  involved  in  vascular  abnormalities  is  the  existence  of
n  arterio-portal  balance  in  human  beings  called  a  ‘‘buffer
ffect’’  which  is  characterized  by  a  compensatory  increase
n  arterial  blood  supply  if  the  portal  supply  falls,  although
he  reverse  does  not  occur  [1].
heoretical bases for studying liver perfusion
andharipande  et  al.  [2]  described  a  list  of  requirements  for
n  ideal  study  of  liver  perfusion:
accurate  quantiﬁcation  of  overall  or  regional  arterial  and.
Signiﬁcance  Units
the  tracer
els  and
Perfusion  pressure  Seconds
into  a
f  time
Tumor
vascularization  and
grade
mL/100  g/min
on  studied Tumor
vascularization,
vascular  or
extracellular  volume
mL/100  g
es  to  cross Perfusion  pressure  Seconds
 the
to  the
Abnormal  vessels  mL/100  g/min
 the
e
Type  of
vascularization
%
n  the
d  the
Equivalent  to  the
permeabil-
ity  ×  perfusion
product
mL/100  g/min
malities;
high  spatial  resolution  which  enables  small  lesions  to  be
examined;
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• high  temporal  resolution  to  correctly  identify  the  kinetic
properties  of  tracers  which  may  differ  within  tissue
lesions;
• measuring  the  concentrations  of  reliable  tracers  for  an
accurate  quantitative  study;
• robust  modeling  of  liver  perfusion  physiology;
• ‘‘whole-liver’’  imaging;
• compatibility  with  morphological  imaging  modalities  to
allow  complementary  perfusion  studies  alongside  more
conventional  investigations.
The  above  list  highlights  the  difﬁculties  in  speciﬁcally
studying  the  liver.  Apart  from  the  known  classical  limitations
of  the  various  instruments  (such  as  accessibility,  cost,  irradi-
ation,  variability  and  dependence  on  the  operator  and  type
of  contrast  medium),  perfusion  imaging  itself  has  other  lim-
itations  and  advantages  depending  on  the  approaches  and
instruments  used.  These  are  summarized  in  Table  2.
The problem of modeling liver perfusion
Modeling  relies  entirely  on  an  analysis  of  the  signal-time
curve  which  is  obtained,  the  shape  of  which  depends  on  the
tissue  properties  studied  (the  perfusion  parameters  mea-
sured,  the  properties  of  the  tracer  bolus  injected  [volume,
injection  rate]  and  the  patient’s  cardiovascular  parameters
[cardiac  output,  ejection  fraction]).
It  should  be  stressed  that  this  study  is  focused  on  tracer
concentrations  rather  than  the  signal.  Therefore,  the  sig-
nal  has  to  be  converted  into  a  concentration.  In  ultrasound,
speciﬁc  software  can  process  the  video-intensity  obtained
and  separate  the  signal  due  to  contrast  from  the  background
noise  (see  details  below).  In  a  CT,  the  relationship  between
tracer  concentration  and  density  is  linear.  In  MRI,  extrac-
tion  of  concentration  from  the  signal  is  more  complicated
and  is  based  on  calibrating  a  sequence  with  tubes  contain-
ing  increasing  doses  of  tracer  and  the  use  of  multiple  angle
tilting  gradients  [3].
There  are  two  main  mathematical  approaches  to  studying
liver  perfusion:
• descriptive  methods  of  signal/time  curve  morphologyare  not  based  on  any  physiological  hypothesis  (free
models)  which  enable  semi-quantitative  parameters  (such
as  enhancement  gradient,  time  to  peak,  area  under  the
Table  2  Advantages  and  limitations  of  imaging  modali-
ties  used  to  study  liver  perfusion.
Ultrasound  CT  MRI
Spatial  resolution  ++  +++  +
Temporal  resolution  +++  ++  ++
Measurement  of  tracer
concentration  alone
++  +++  +
‘‘Whole-liver’’  imaging  +  +  +++
Modeling  +/−  +/−  +/−
Compatibility  with
morphological
imaging
++  +++  ++
+: average; ++: good; +++ excellent; +/−:  problematic.
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curve)  to  be  extracted.  These  are  used  in  ultrasound  (see
below)  and  in  CT  and  MRI  [4,5]. However,  this  analysis
varies  considerably  depending  on  the  acquisition  method
used  for  each  individual  investigation  and  according  to  the
imaging  instrument  used;
pharmacokinetic  models  incorporate  the  speciﬁc  restric-
tions  of  liver  perfusion  to  a  greater  or  lesser  extent.
These  models  are  based  on  determining  the  relation-
ship  between  arterial  input  function  alone  (in  the  tumor
application)  and  the  arterial-portal  input  functions  (in
diffuse  disease),  obtained  from  the  enhancement  curve
from  afferent  blood  vessels.  Deconvolution  algorithms
[6]  and  compartmental  models  [3,7]  belong  to  this  cate-
gory.  These  models  assume  that  there  are  several  hepatic
compartments  in  which  the  contrast  medium  is  present,
mixed  in  a  uniform  concentration  throughout  the  com-
partment,  that  ﬂow  is  linear  between  compartments
(passive  exchange  only)  and  that  the  parameters  which
describe  the  compartments  are  invariant  during  the  data
acquisition.  Depending  on  the  model,  the  parameters  of
interest  are  then  extracted  (Table  1).  The  CT  models  vary
depending  on  the  number  of  compartments  and  afferent
blood  vessels.  The  Tofts  model  (or  modiﬁed  Tofts)  is  often
used  in  MRI  clinical  research.  It  circumvents  the  arterial
input  function  and  considers  the  whole  vascular  compart-
ment.
As  shown  in  the  CT  sample  by  Kanda  et  al.  and  Goh  et  al.
8,9],  the  data  obtained  are  not  independent  from  the  model
sed.  The  choice  of  model  depends  on  the  organ  being  stud-
ed  and  the  experience  of  the  users  and  makes  it  difﬁcult  to
eneralize  ﬁndings.
ifferent study models in perfusion
maging
sotopic imaging
cintigraphic  methods  to  calculate  liver  perfusion  parame-
ers  were  ﬁrst  described  in  the  1970s.  Images  are  generally
cquired  every  1  to  2  seconds  after  intravenous  injection  of  a
adiopharmaceutical  (technetium  99m  pertechnetate,  albu-
in  or  sulfur-based  colloids).  Liver  enhancement  is  analyzed
y  regions  of  interest  (ROI)  and  the  arterial  and  portal  com-
onents  are  separated,  working  on  the  principle  that  the
enal  enhancement  peak  represents  the  beginning  of  portal
nhancement  of  hepatic  parenchyma  [10—16]. The  impor-
ant  parameter  is  the  hepatic  artery  perfusion  index  deﬁned
s  A/(A  +  P)  where  A  is  the  arterial  enhancement  gradient
nd  P  is  the  portal  enhancement  gradient.
Scintigraphic  studies  based  on  positron  emission  tomo-
raphy  (PET)  have  recently  assessed  the  feasibility  of
tudying  hepatic  perfusion  [17]. Isotopic  imaging,  however,
s  hindered  by  poor  spatial  and  temporal  resolution.
ltrasoundoppler  ultrasound  quantiﬁes  ﬂows  rather  than  perfusion.
n  order  to  examine  perfusion,  mean  ﬂow  velocity  is  mul-
iplied  by  the  diameter  of  the  blood  vessel.  An  alternative
pproach  is  to  calculate  the  difference  between  the  time
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aken  for  an  ultrasound  beam  to  travel  a  deﬁned  distance
n  the  direction  of  ﬂow  and  counterﬂow.  Trans-abdominal
easurement  of  hepatic  arterial  (A)  and  portal  (P)  ﬂow  and
he  hepatic  Doppler  perfusion  index  can  be  calculated  from
he  equation  A/(A  +  P).  The  major  disadvantages  of  these
pproaches  are  inter-  and  intra-observer  variability  and  the
nability  to  obtain  regional  ﬁndings.
Contrast-enhanced  ultrasound  (CEUS)  with  microbubble
ontrast  agents  is  a  more  recent  technique  which  is  used  to
uantify  tissue  perfusion.  CEUS  has  several  advantages  over
ther  imaging  modalities  in  measuring  tissue  perfusion:  it
ses  purely  endovascular  agents  which  circumvent  the  issue
f  extravascular  leakage,  are  readily  available  and  do  not
nvolve  exposure  to  X-rays  or  radionuclide  tracers.
Dynamic  image  sequences  are  obtained  after  injection
f  the  contrast  medium,  which  then  varies  in  local  concen-
ration  over  time.  These  images  represent  the  changes  in
ntensity  over  time,  which  can  then  be  modeled  in  order  to
btain  parameters  describing  the  microcirculation.  Micro-
irculation  is  based  on  a  precise  distinction  between  the
ackscatter  signals  from  the  microbubbles  and  from  the
urrounding  native  tissue.  Speciﬁc  software  is  needed  to
uantify  signal  intensity  and  allow  tissue  contrast  uptake
o  be  calculated.
In  practice,  if  uncompensated  attenuation  effects  are
ssumed  to  be  negligible,  grey  scale  (from  0  to  255)  image
ntensity  quantiﬁcation  (videodensitometry)  is  the  most
idely  available  technique  to  measure  the  response  to  the
ontrast  medium  in  clinical  practice.  The  signal  is  gener-
lly  compressed  logarithmically  and  image  intensity  is  then
roadly  similar  to  the  logarithm  of  the  backscatter  coefﬁ-
ient  value  and  therefore  to  the  logarithm  of  the  number
f  microbubbles  present.  However,  this  technique  does  not
heoretically  provide  an  accurate  measurement  without  bias
rom  the  diffusion  coefﬁcient  because  of  the  many  signal
rocessing  stages  required.
In  order  to  more  closely  reﬂect  the  direct  relationship
etween  signal  and  the  backscatter  coefﬁcient,  some  ultra-
ound  manufacturers  now  offer  quantiﬁcation  software  that
s  called  ‘linear  of  the  signal’,  using  the  principle  of  studying
he  signal  value  in  a  region  of  interest  (ROI)  deﬁned  from
aw  image  data  before  processing  the  video  signal.  These
oftware  solutions  therefore  circumvent  the  ﬁnal  stages  of
ogarithmic  compression  and  extrapolation.
The  three  main  methods  for  ultrasound  measurement
f  tissue  perfusion  are  measurement  of  organ  transit
ime,  analysis  of  tissue  reperfusion  kinetics  and  analysis  of
nhancement  intensity  curves  [18].
easurement  of  organ  transit  time
n  the  liver,  the  time  between  injection  or  arrival  in  the
epatic  artery  of  the  contrast  medium  and  the  ﬁrst  appear-
nce  of  contrast  medium  in  a  hepatic  vein  can  be  measured.
o  do  this,  a  hepatic  vein  is  targeted  and  kept  within  the  ﬁeld
f  vision  before  injection.  The  acquisition  is  taken  with  the
ubject  breathing  slowly  and  freely.  The  time  taken  for  the
ontrast  to  arrive  is  generally  over  30  seconds  in  normal  sub-
ects  (the  lower  limit  of  the  normal  has  been  reported  to  be
5  seconds)  [19,20].  This  technique  is  particularly  useful  for
nvestigating  patients  with  diffuse  liver  disease,  but  has  also
een  studied  in  patients  with  liver  metastases.
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eperfusion  methods
 state  of  equilibrium  is  reached  after  2—3  minutes  when  the
icrobubbles  are  administered  as  a continuous  infusion.  At
teady  state,  microbubble  arrival  and  departure  from  any
icrocirculatory  unit  is  constant  and  proportional  to  the
ractional  blood  volume  in  this  unit.  It  only  depends  on  the
peed  of  microbubble  ﬂow.  Local  tissue  perfusion  can  then
e  calculated  by  analyzing  the  reconstitution  kinetics  of  the
olume  of  microbubbles  after  they  have  been  destroyed  by
igh  initial  power  insonation  [21,22].  After  the  microbubbles
ave  been  destroyed,  the  system  switches  to  a  low  emission
ower  in  order  to  study  the  microbubble  ﬁlling  rate.  One  of
he  main  limitations  of  the  technique  is  that  the  perfusion
ata  are  obtained  from  a  single  tissue  plane,  a  situation
hich  is  not  particularly  useful  in  accurately  reﬂecting  over-
ll  perfusion  of  the  tissue  or  organ  during  the  investigation.
D  volumetric  and  reperfusion  studies  are  complex  and  have
ot  yet  been  completely  modeled.  Analysis  of  the  ﬁlling
rocess  provides  semi-quantitative  data  linked  to  tissue  per-
usion  values:  the  time  to  peak,  initial  slope  of  reperfusion,
aximum  reﬁlling  curve  amplitude,  area  under  the  curve
related  to  blood  volume)  and  mean  transit  time  [23,24].
nalysis  of  enhancement  intensity  curves
fter  a  bolus  of  contrast  has  been  injected,  changes  in
ntensity  over  time  during  the  ﬁlling  phase  (wash-in)  and
limination  phase  (wash-out)  of  the  bolus  are  studied  to
stimate  the  microcirculation.  Different  imaging  modalities
se  identical  methods,  the  most  widely  used,  as  described
bove,  being  compartmental  modeling.  This  requires  access
o  an  arterial  input  which  is  used  as  the  input  function,  that
s  often  difﬁcult  obtain  on  CEUS.  Deconvolution  and  behav-
oral  models  are  therefore  difﬁcult  to  use.  As  a  result,  solely
he  descriptive  parameters  are  extracted  from  the  bolus
inetics.  The  most  widely  used  are  the  maximum  intensity
eak  (i.e.  maximum  intensity),  the  time  to  maximum  inten-
ity  peak,  the  width  of  the  maximum  intensity  peak,  mean
ransit  time  and  the  area  under  the  curve.
omputed tomography
he  tracer  used  in  CT  is  a  concentrated  iodinated  contrast
edium  injected  at  high  ﬂow.  In  principle,  CT  has  many
dvantages.  It  is  readily  accessible,  inexpensive,  quick  and
ighly  reproducible.  It  offers  good  spatial  and  temporal  res-
lution  and  quantiﬁcation  of  the  tracer  is  straightforward  as
he  density  concentration  relationship  is  linear  (Figs.  1—3)
nd  it  also  provides  morphological  information.  Its  disadvan-
ages  are  well  known  and  classic:  radiation  and  injection
f  iodinated  contrast.  The  additional  radiation,  however,
s  low  and  can  be  reduced  by  optimizing  the  acquisition
ettings,  improving  detectors  and  using  reconstruction  algo-
ithms  [25,26].
The  acquisition  settings  vary  depending  on  the  author.  As
 guide,  in  our  experience  with  a  64-slice  instrument  the
cquisition  settings  are:  80  kV,  100  mAs,  512  ×  512  square
atrix,  1  second  rotation  time,  simultaneous  acquisition  of
ight  transverse  sections  (8  sections  per  rotation),  each  with
 thickness  of  5  mm.  In  order  to  reduce  radiation,  the  images
re  acquired  each  second  for  30  seconds  and  then  every
 seconds  up  to  2  minutes.  The  total  number  of  images  per
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Figure 1. Example of signal to time curve obtained on CT. On the left, axial section passing through the gallbladder. The signal to time
curve (image on the right) is obtained after positioning the regions of interest in the afferent vessels (aorta and portal vein). The change in
tracer concentration over time is obtained by rapid signal sampling (in t
analysis of these curves.
Figure 2. Diagram showing the models used to analyze the signal-
time curve.
Figure 3. A display of semi-quantitative parameters obtained
from a descriptive analysis of the morphological properties of the
signal-time curve. EI: enhancement intensity; TTP: time to peak
enhancement; AUC: area under the curve; Gradient: gradient of
the entry phase; FWHM: full width at half maximum.
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Mhis case density). The perfusion parameters are extracted from an
atient  is  400  and  the  total  acquisition  time  is  2  minutes.
he  iodinated  contrast  (containing  350  mg  of  iodine/mL)  is
dministered  as  40  mL  into  an  antecubital  vein  at  a  rate
f  4  mL/s.  In  order  to  reduce  respiratory  artefacts  during
he  investigations,  patients  are  asked  to  breathe  slowly  and
uperﬁcially  and  are  told  about  the  possible  ﬂush  sensation
hey  may  experience  after  the  injection.  The  investigation
akes  an  average  total  time  of  15  minutes.  The  radiation
ose  delivered  under  these  conditions  is  in  the  region  of
0—15  Sv.
RI
n  1999,  Scharf  et  al.  described  a  signiﬁcant  correlation
etween  MRI  and  thermal  dilution  probe  ﬂow  measurements
n  pigs  using  1.0  T  T1-weighted  sequences  [27].  MRI  has  good
patial  and  temporal  resolution  and  does  not  necessitate
adiation.
The  most  common  methods  used  for  MRI  measurement
f  perfusion  are  dynamic  contrast-enhanced  MRI  (DCE-MRI)
fter  injection  of  a gadolinium  chelate,  arterial  spin  label-
ng  and  dynamic  contrast  susceptibility  MRI  (DCS-MRI)  [28].
he  ﬁrst  of  these  approaches  is  by  far  the  most  commonly
sed.  Unlike  CT,  in  which  the  tracer  concentration  curve
ver  time  is  proportional  to  changes  in  attenuation  mea-
ured  in  Hounsﬁeld  units,  the  curve  is  more  difﬁcult  to
btain  in  MRI  as  the  relationship  between  signal  intensity  and
racer  concentration  is  not  linear.  Concentration  is  related
o  the  relaxivity  of  the  medium  and  requires  measurement
f  T1  which  can  be  performed  using  samples  of  increasing
adolinium  concentration.  Whilst  most  groups  use  conven-
ional  gadolinium  chelates,  some  very  recent  studies  have
sed  liver  speciﬁc  contrast  media  and  have  reported  similar
esults  [29].
Finally,  the  sequences  which  are  affected  by  molecular
iffusion  (diffusion  MRI)  are  inﬂuenced  by  the  microperfu-
ion.  This  is  the  IVIM  (intravoxel  incoherent  motion)  model,
he  concept  of  which  was  initially  introduced  and  developed
y  Le  Bihan  et  al.  [30]  to  quantitatively  measure  all  micro-
copic  movements  which  could  contribute  to  the  diffusion
RI  signal.  These  movements  in  biological  tissues  are  mostly
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ue  to  molecular  diffusion  of  water  and  to  microcirculation
f  blood  in  the  capillary  network  (perfusion).  The  concept
ntroduced  by  Le  Bihan  et  al.  was  that  water  circulating
n  randomly  oriented  capillaries  (at  a  voxel  level)  imitates
andom  motion  (‘‘pseudodiffusion’’).  This  leads  to  attenua-
ion  of  the  diffusion  MRI  signal  which  depends  on  the  speed
f  the  circulating  blood  and  the  vascular  architecture.  As
ith  true  molecular  diffusion,  the  effect  of  pseudodiffusion
n  signal  attenuation  depends  on  the  b  value.  The  amount
f  signal  attenuation  occurring  as  a  result  of  pseudodiffu-
ion,  however,  is  of  an  order  of  magnitude  greater  than
olecular  diffusion  in  tissues  and,  as  a  result,  the  relative
ontribution  to  the  diffusion-weighted  signal  only  becomes
igniﬁcant  at  very  low  b  values,  theoretically  allowing  the
iffusion  and  microperfusion  components  to  be  separated.
n  initial  experimental  study  showed  that  rats  suffering  from
iver  ﬁbrosis  had  reduced  in  vivo  ADC  (apparent  diffusion
oefﬁcient)  values  compared  to  controls,  although  that  this
ifference  disappeared  ex  vivo  [31].  A  clinical  study  pub-
ished  by  Luciani  et  al.  in  patients  suffering  from  cirrhosis
ompared  to  volunteers  conﬁrmed  the  fall  in  ADC  in  cirrhotic
atients  and  showed  that  the  restriction  in  diffusion  which
as  seen  was  due,  in  large  part,  to  changes  in  microperfu-
ion  components  and,  to  a  lesser  extent,  to  a  reduction  in
ure  hepatic  diffusion  [32].  Several  areas  of  research  have
ince  opened  as  a  result  of  this  approach,  particularly  in
umor  imaging.
he liver: a large mobile organ
he liver is a mobile organ
adiographic  studies  using  ﬁxed  landmarks,  radioscopy  and
ven  CT  [33]  have  shown  that  the  liver  is  an  organ  which
oves  considerably  with  respiration,  shifting  approximately
0  mm  along  its  cranio-caudal  axis,  10  mm  along  its  antero-
osterior  axis  and  5  mm  laterally.  This  raises  major  questions
or  infusion  imaging,  the  aim  of  which  is  to  obtain  a  quanti-
ative  pixel  scale  assessment.  Several  CT  and  MRI  techniques
ave  been  described  to  compensate  for  these  movements,
ncluding  respiratory  monitoring  when  the  acquisition  is
aken  with  a  belt  or  a  dedicated  sequence  and  adjustment
f  images  acquired  manually,  semi-automatically,  rigidly  or
on-rigidly.  The  results  obtained  vary.  However,  comparisons
etween  different  adjustment  methods  have  shown  that
he  non-rigid  semi-automated  methods  appear  to  be  more
obust  [34].  Attempts  to  introduce  image  adjustment  meth-
ds  are  currently  being  evaluated  for  ultrasound,  although  in
ost  studies  no  method  is  available  to  correct  for  respiratory
ovements.
he liver is a large organ
deally,  a  perfusion  study  should  examine  the  whole  organ,
lthough  in  practice  the  acquisition  is  often  limited  to  a  thick
ection,  as  in  our  CT  protocol  example.  This  does  not  raise
any  problems  for  investigations  focused  on  tumors  closeo  the  large  vessels  but  does  raise  an  issue  when  the  lesions
re  located  in  the  dome,  when  it  is  very  difﬁcult  to  obtain
cquisitions  of  the  lesion  and  the  portal  vessels  within  one
cquisition.
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Recent  CT  and  MRI  studies  have  taken  account  of  this
ssue.  Authors  of  CT  studies  describe  the  use  of  machines
ith  wide  area  coverage  (128  to  320  slice)  [35]  or  dynamic
piral  techniques  (Jog  mode)  based  on  a short  forward
nd  return  of  the  table  past  the  detectors  to  obtain  the
quivalent  to  wide  area  coverage  (240  slice  detectors),  but
sing  64-  or  128-slice  instruments  [36].  Rapid  dynamic  3D
equences  have  been  described  for  MRI  which  require  a
ompromise  to  be  made  vis-à-vis  the  instrument’s  temporal
esolution  [37,38].
he reproducibility problem
he  combination  of  variable  results  depending  on  the  instru-
ents,  patient  respiration  problems  and  total  liver  perfusion
eads  to  different  results  being  obtained  both  between
atients  and  in  the  same  patient.  Ng  et  al.  [39]  showed  that
he  variation  for  some  parameters  could  be  as  great  as  75%
nd  concluded  that  absolute  perfusion  parameters  are  not
vailable  and  that  the  results  obtained  from  perfusion  data
eed  to  be  interpreted,  paying  particular  attention  to  the
cquisition  protocols  and  analytical  methods.
A  few  studies  have  also  attempted  to  compare  the  results
btained  with  the  different  imaging  modalities.  Lefort  et  al.
40]  and  Goetti  et  al.  [41]  compared  contrast  ultrasound
nd  perfusion  CT  and  showed  a  modest  correlation  (r  ranged
rom  0.45  to  0.75).
iver imaging applications
etection of liver metastases
he  presence  of  established  metastases  in  the  liver  produces
emodynamic  changes,  with  an  increase  in  arterial  perfusion
nd  reduction  in  portal  perfusion.  These  were  ﬁrst  reported
n  scintigraphy  and  CT  [5,42—44]  and  then  conﬁrmed  in
RI  [45]. However,  these  changes  are  of  limited  use  as  the
umors  are  already  established.
Studies  which  show  similar  results  for  occult  metastases
6,46,47]  are  of  more  interest,  although  these  have  not  been
onﬁrmed  in  human  beings.  A  multicentre  French  PHRC  (hos-
ital  clinical  research  program)  study  which  included  over
00  patients  and  ﬁnished  in  2012  will  attempt  to  establish
he  prognostic  value  of  perfusion  indices  in  terms  of  devel-
pment  of  liver  metastases  in  people  suffering  from  colonic
ancer.
umor characterization
erfusion  has  been  studied  mostly  as  an  indicator  in  hepa-
ocellular  carcinoma  (HCC),  to  assess  tissue  differentiation
Fig.  4)  and  to  distinguish  between  a  dysplastic  nodule  and
CC.  The  imaging  appearances  of  HCC  typically  include
ntense  arterial  enhancement  and  a  portal  or  late  stage
ash-out.  Perfusion  imaging  shows  an  increase  in  blood  vol-
me,  blood  ﬂow  and  permeability  although  a  lower  mean
ransit  time  compared  to  the  adjacent  liver.  A  relationship
as  been  found  between  tumor  differentiation  and  perfusion
arameters  [48,49]. In  addition,  because  of  the  arterial  sup-
ly  to  the  tumor,  differences  in  perfusion  have  been  shown
n  the  presence  or  absence  of  portal  vein  thrombosis  [49].
Can  we  justify  not  doing  liver  perfusion  imaging  in  2013?  1329
Figure 4. Hepatocellular carcinoma (HCC) in a 54-year-old patient with viral hepatitis C cirrhosis investigated by liver perfusion CT. The
lesion is clearly demarcated and hypervascular with wash-out (left column). The four images on the right show four parameter charts
(vascular volume, arterial index, perfusion and mean transit time). In this case, the lesion is preferentially supplied by the hepatic artery
and has a greater vascular volume and perfusion than the adjacent liver. The mean transit time is prolonged, which is unusual in these
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Assessing response to treatment
Locoregional  therapy:  the  example  of
chemo-embolization
Perfusion  investigations  in  locoregional  therapies  for  liver
tumors,  particularly  HCC,  have  little  to  offer  in  percuta-
neous  ablation  (such  as  radiofrequency  or  microwave)  as
the  response  and  relapse  criteria  are  well  described  and
robust  [50,51].  However,  a  study  by  Meijerink  et  al.  [52]
did  conclude  that  investigation  of  hepatic  vascular  volume
appeared  to  be  useful  in  detecting  and  locating  recurrences
in  contact  with  the  ablation  impact  sites.
Many  studies  have  been  published  on  chemo-
embolization.  Results  from  a  rabbit  model  have  validated
the  use  of  perfusion  CT  [53]  and  MRI  [54]  to  quantify  tumor
perfusion  after  several  successive  embolization  sequences.
More  recently,  Choi  et  al.  carried  out  a  prospective  assess-
ment  of  the  feasibility  of  perfusion  CT  as  a  follow-up
method  after  hepatic  artery  chemo-embolization  and
showed  early  perfusion  changes  (at  1  week)  which  were
different  in  the  treated  areas  compared  to  untreated  areas.
They  concluded  that  perfusion  CT  is  useful  in  assessing
rapid  response  and  in  detecting  tumor  recurrence  early,
after  treatment  [55].
There  are,  however,  only  a  few  studies  in  human  beings.
Ippolito  et  al.  examined  perfusion  parameters  in  tumor
residues  following  treatment  and  showed,  as  Choi  did  in
animals,  differences  from  the  successfully  treated  areas
[56].  These  ﬁndings  show  the  direction  of  current  research:
s
(
o
narly  identiﬁcation  of  responders  and  non-responders  for
rompt  change  in  management.  Other  groups  have  shown
erfusion  changes  on  MRI  during  the  procedure  [57,58].  Per-
usion  is  therefore  considered  to  be  a  prognostic  biomarker.
inally,  Michielsen  et  al.  studied  perfusion’s  capacity  to
redict  disease-free  progression  (DFP)  in  patients  suf-
ering  from  inoperable  hepatocellular  carcinoma  treated
ith  chemo-embolization  and  concluded  that  the  param-
ters  studied  (area  under  the  curve  [AUC],  initial  slope
IS],  and  time  to  peak  [TTP])  were  predictive  indicators
or  disease-free  survival  which  were  independent  of  the
ize  and  number  of  lesions.  In  this  case,  the  role  of
he  biomarker  was  examined  as  a  predictive  indicator  of
esponse  [59].
ystemic  chemotherapy  and  targeted  therapies
his  research  is  based  on  the  principle  of  studying
arly  perfusion  changes  in  treated  tumors,  particularly
n  patients  treated  with  anti-angiogenics  (such  as  anti-
EGFR)  (Figs.  5  and  6).  This  is  an  extremely  interesting
rea,  although  at  present  there  is  a  lack  of  large  pub-
ished  series  and  radiopathologic  correlation.  Most  of  the
ublished  ultrasound  studies  are  limited  to  descriptive  anal-
ses  of  changes  in  ultrasound  enhancement  curves.  Lassau
t  al.  [60,61]  showed  that  early  changes  (D0  to  D3)  in
everal  parameters  were  associated  with  tumor  response
particularly  the  area  under  the  curve  and  the  intensity
f  the  enhancement  peak)  and  that  some  even  had  prog-
ostic  value  in  terms  of  disease-free  progression  (intensity
1330  M.  Ronot  et  al.
Figure 5. Hepatocellular carcinoma (HCC) in a 54-year-old patient with viral hepatitis C cirrhosis investigated by hepatic perfusion CT
(same lesion as in Fig. 4) after 1 month of treatment with sorafenib. Two regions are seen within the tumor. Region 1 has similar perfusion
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seatures to those of the tumor before treatment (table on the righ
n mean transit time in relation to local response to treatment.
f  enhancement  peak)  or  overall  survival  (area  under  the
urve).
MRI  studies  based  on  the  same  analytical  methods  are
escribed  [62],  and  the  ﬁrst  studies  using  Bloomley  free
odels  [63]  or  pharmacokinetic  models  [64—66]  have  been
ublished.  The  aim  of  these  studies  was  again  to  use
erfusion  as  a  prognostic  biomarker  by  correlating  early
esponse  with  long-term  survival,  or  as  a  response  biomarker
y  demonstrating  differences  in  the  parameters  before
reatment  in  future  responders  compared  to  future  non-
esponders,  as  reported  in  the  recent  study  published  by
su  [66].
hronic diffuse diseases
he  development  of  liver  ﬁbrosis  and  progression  of  ﬁbrosis
o  cirrhosis  is  associated  with  vascular  and  perfusion  micro-
rchitectural  changes:  the  sinusoids  are  gradually  converted
nto  continuous  non-fenestrated  capillaries  demarcated  by
n  organized  basal  membrane  containing  laminin,  with  an
ncrease  in  vascular  resistance  and  fall  in  portal  perfusion
hich  is  partly  compensated  by  an  increase  in  arterial
erfusion  (buffer  effect)  and  later  by  an  overall  fall  in  per-
usion.  These  ﬁndings  have  been  obtained  from  scintigraphic
tudies.
In  echography,  the  ultrasound  organ  transit  time  method
howed  a  decreased  contrast  bolus  arrival  time  (<  24  s)  in
irrhosis,  with  a  left  shift  in  the  time  intensity  curve  due  to
he  increased  arterial  supply  and  intrahepatic  shunts.  The
ame  approach  has  been  used  to  assess  the  severity  of  dif-
use  liver  disease  [67],  and  to  distinguish  between  mild  and
s
[
f
bgion 2 shows a fall in perfusion and vascular volume with increase
oderate/severe  ﬁbrosis  in  patients  with  chronic  hepatitis
68].
Miles  et  al.  and  Blomley  et  al.  [4,5]  have  demon-
trated  the  buffer  effect  via  the  gradient  method  in
erfusion  scanning  and  Van  Beers  et  al.  reported  an
ncrease  in  the  arterial  fraction  and  mean  transit  time  in
 compartmental  model  in  a  group  of  cirrhotic  patients
ompared  to  a  control  group  (41  ±  27%  compared  to
7  ±  16%  and  51  ±  79  s  compared  to  16  ±  5  s).  They  also  high-
ighted  the  fall  in  overall  perfusion  compared  to  livers
n  the  control  group  (0.67  ±  0.23  mL/min/mL  compared  to
.08  ±  0.34  mL/min/mL)  [69].  The  increase  in  mean  transit
ime  was  attributed  to  reducing  mobility  of  the  low  molecu-
ar  weight  tracer  molecules  in  the  Disse  space  of  the  ﬁbrotic
ivers,  as  mobility  was  preserved  and  the  volumes  at  distri-
ution  were  unchanged.  More  recently,  we  have  described
he  use  of  perfusion  CT  to  distinguish  the  early  stages  of
brosis  [70].
The  MRI  studies  which  have  been  published  have  mostly
een  on  animal  models  [3,71,72], and  have  conﬁrmed  the
arlier  studies  which  reported  similar  results  with  albumin.
here  have  been  few  MRI  studies  on  chronic  liver  disease
n  human  beings.  Annet  et  al.  described  a  reduction  in  por-
al  perfusion  and  an  increase  in  arterial  perfusion  and  the
ean  transit  time  in  established  cirrhosis  [73]. We  have  also
hown  changes  in  these  parameters  with  progression  of  ﬁbro-
is  before  the  development  of  cirrhosis  in  an  unpublished
tudy  whose  data  have  been  corroborated  by  Hagiwara  et  al.
37]. No  studies  have  been  carried  out  in  this  area  in  the  dif-
erent  stages  of  ﬁbrosis  classiﬁed  in  routine  clinical  practice
y  the  METAVIR  score.
Can  we  justify  not  doing  liver  perfusion  imaging  in  2013?  1331
Figure 6. Inﬁltrating hepatocellular carcinoma (HCC) in viral hepatitis C cirrhosis treated with an anti-angiogenic (sunitinib), investigated
by liver perfusion CT. The ﬁgure is read by line and column. The upper line (A—C) shows three arterial phase sections taken in March, April
and June of the same year. The HCC is an inﬁltrating hypervascular mass. The second line (D—F) shows perfusion parameter charts voxel by
voxel on the same three dates. High ﬂow is shown in red and low ﬂow in blue. The lower line (G—I) shows blood volume parameter charts
voxel by voxel on the same three dates. High ﬂow is shown in red and low ﬂow in blue. The ﬁrst column (A, D and G) shows the investigation
before starting treatment. The middle column (B, E and H) is the investigation after starting treatment. Tumor response is reﬂected by
necrosis, seen as a hypodense area on CT (B), and a fall in tumor perfusion (E) and tumor blood volume (H). The last column (C, F and I)
shows the tumor failing to respond to treatment with further lesional growth on the periphery (C), and an increase in perfusion (F) and
tumor blood volume (I).
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onclusion
erfusion  studies  are  a  useful  tool  in  liver  imaging,  although
any  methodological  problems  need  to  be  resolved  before
t  is  implemented.  Whilst  the  use  of  perfusion  is  currently
argely  limited  to  research,  encouraging  results  have  been
ublished.  Findings  from  perfusion  studies,  however,  suf-
er  from  a  lack  of  standardization  as  the  models  and  the
achines  vary  and  the  series  are  small  and  single-centred.
 group  effort  is  required  to  harmonize  practices  and  incor-
orate  perfusion  into  a  multiparameter  approach.
TAKE-HOME  MESSAGES
General  points
• Liver  perfusion  imaging  is  the  study  of  descriptive
quantitative  parameters  of  liver  perfusion
physiology.
• The  liver  has  a  dual  blood  supply.  Approximately  25%
of  total  blood  supply  comes  from  the  hepatic  artery
and  the  remaining  75%  from  the  portal  vein.
• The  basic  hypothesis  on  which  liver  perfusion  imaging
is  based  is  that  focal  or  diffuse  pathological  processes
lead  to  measurable  changes  in  these  perfusion
parameters.
Difﬁculties  with  modeling
• Perfusion  parameters  are  extracted  from  an  analysis
of  the  signal  to  time  curve.
• There  are  two  major  mathematical  approaches  to
studying  liver  perfusion:  descriptive  signal  to  time
curve  methods  and  pharmacokinetic  models.
• The  descriptive  approach  is  not  based  on  any
physiological  hypothesis  and  is  used  to  extract  semi-
quantitative  parameters  from  the  morphology  of  the
time-signal  curve  (enhancement  gradient,  time  to
peak,  area  under  the  curve).
• The pharmacokinetic  models  incorporate  the  speciﬁc
limitations  of  liver  perfusion.  These  mostly  involve
deconvolution  models  and  the  compartmental
approach.
• The  data  obtained  are  not  independent  of  the  model
used.
Different  imaging  methods  for  studying  perfusion
• Perfusion  can  be  studied  by  isotopic,  ultrasound,  CT
and  MR  imaging.
• Contrast  agents  containing  microbubbles  are  used  to
quantify  tissue  perfusion  in  ultrasound.
• The  three  main  methods  used  to  evaluate  tissue
perfusion  by  contrast-enhanced  ultrasound  are
measurement  of  the  organ  transit  time,  analysis
of  tissue  reperfusion  kinetics  and  analysis  of  the
enhancement  intensity  curves.  The  last  of  these  is
the  most  widely  used.
• The  tracer  used  for  CT  is  a  concentrated  iodinated
contrast  medium  injected  at  high  ﬂow.  The  curve  of
tracer  concentration  against  time  is  proportional  to
changes  in  attenuation  measured  in  Hounsﬁeld  units
(density).
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• The  most  widely  used  MRI  method  to  measure
perfusion  is  dynamic  contrast-enhanced  MRI  (DCE-
MRI)  after  an  injection  of  gadolinium  chelate.
• In  MRI,  the  intensity  relationship  between  the
signal  and  concentration  of  the  tracer  is  non-linear
although  it  is  related  to  the  relaxivity  of  the
environment  and  requires  calibration.
• The  IVIM  MRI  model  (intravoxel  incoherent  motion)
can  be  used  in  diffusion  imaging  to  assess  the
microperfusion.
Liver  imaging  applications
• The  major  indications  are  detection  of  liver
metastases,  characterization  of  tumors,  assessing
tumor  response  and  studying  diffuse  liver  disease.
• Established  metastases  in  the  liver  cause
hemodynamic  changes,  with  an  increase  in  arterial
perfusion  and  a  fall  in  portal  perfusion.  Studies  to
assess  the  role  of  perfusion  in  occult  metastases  are
ongoing.
• In  HCC,  there  is  a relationship  between
tumor  differentiation  and  perfusion  parameter
values.
• Studies  of  tumor  response  have  mostly  been  carried
out  in  HCC  with  the  aim  of  using  perfusion
imaging  as  a  biomarker  for  response  or  prognosis  by
demonstrating  early  changes  in  perfusion  parameters
in  responders.
• In  chronic  liver  disease,  perfusion  parameters  change
as  the  ﬁbrosis  progresses.
• In  established  cirrhosis,  perfusion  imaging  shows
a  reduction  in  portal  perfusion  and  an  increase
in  arterial  perfusion  and  the  mean  transit
time.
linical case report
his  53-year-old  man  has  chronic  viral  hepatitis  C  with  histo-
ogically  proven  cirrhosis.  A  focal  right  posterior  lesion  was
ound  on  ultrasound  monitoring  and  as  a  result  this  CT  was
erformed  (Fig.  7).
uestions
.  Based  on  the  ﬁndings  from  the  CT  (Fig.  7),  what  would
our  diagnosis  be?  How  would  you  conﬁrm  it?
A  liver  resection  was  organized  and  the  patient  was
ncluded  in  a  clinical  trial  with  a  targeted  neo-adjuvant
herapeutic  molecule.  Perfusion  imaging  before  beginning
reatment  and  after  starting  the  targeted  therapy  was  orga-
ized  as  part  of  the  trial  (Fig.  8).
2.  Describe  the  perfusion  parameters  of  the  lesion  on
ig.  8.
3.  Looking  at  the  images  on  Fig.  8, can  you  tell  which
nalytical  model  was  used?4.  The  baseline  investigation  (pre-treatment)  showed  an
ncrease  in  perfusion  and  vascular  volume  and  a  low  mean
ransit  time.  What  is  your  conclusion  on  the  perfusion  imag-
ng  after  treatment  (Fig.  8)?
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Figure 7. Abdominal CT passing through the liver after iodinated contrast enhancer injection with triphasic acquisition in the arterial
(a), venous (b) and late (c) phases.
ur paFigure 8. Perfusion CT centered on the right posterior lesion. Fo
mean transit time (c), and arterial index (d).Answers
1.  The  CT  shows  a  single  subcapsular  lesion  located  in
the  lower  part  of  segment  VII.  The  lesion  is  hypervascular
a
h
1
nrameter charts are shown: vascular volume (a), vascular ﬂow (b),nd  exhibits  wash-out  in  the  late  venous  phase.  As  it
as  developed  in  the  cirrhotic  liver  and  is  more  than
0  mm  in  diameter,  it  meets  all  of  the  criteria  for  a
on-invasive  diagnosis  of  hepatocellular  carcinoma  and
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he  diagnosis  therefore  requires  no  further  investiga-
ions.
2.  The  four  images  show  four  parameter  charts:  vascular
olume  (a),  arterial  blood  ﬂow  (b),  mean  transit  time  (c)
nd  arterial  index  (d).  The  lesion  is  supplied  preferentially
y  the  hepatic  artery  (d)  and  has  a  lower  vascular  volume
nd  perfusion  than  the  adjacent  liver  (a  and  b).  The  mean
ransit  time  is  identical  to  that  of  the  adjacent  liver  (c).
3.  As  the  parameters  shown  are  quantitative  and  based  on
iver  physiology,  this  is  not  a  descriptive  analysis  of  the  signal
o  time  curve  morphology  and  the  model  used  is  therefore
 pharmacokinetic  model.  However,  the  parameter  charts
lone  do  not  show  us  which  speciﬁc  model  has  been  used.  We
an  see  that  this  model  incorporates  two  vascular  supplies
artery  and  portal  vein)  in  order  to  calculate  the  arterial
ndex  (d)  and  that  it  includes  a  calculation  of  the  volume
f  the  vascular  compartment.  For  information  purposes,  in
his  case,  this  is  a  deconvolution  model.
4.  By  comparing  the  baseline  investigation  and  Fig.  8,
e  can  see  that  the  lesion’s  volume  and  vascular  ﬂow  have
educed  and  the  mean  transit  time  has  increased  after  treat-
ent.  These  appearances  reﬂect  a  change  in  vascularization
f  the  lesion  and  probably  represent  an  early  response  to
tarting  targeted  therapy.
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